BETWEENLicense and Research Collaboration Agreement • March 15th, 2004 • Decode Genetics Inc • Services-commercial physical & biological research • New Jersey
EXCLUSIVE LICENSE AND RESEARCH COLLABORATION AGREEMENTLicense and Research Collaboration Agreement • May 26th, 2004 • Metabasis Therapeutics Inc • Pharmaceutical preparations
This Agreement (this "Agreement") is dated as of December 23, 2003 (the "Effective Date"), and is entered into by and between MERCK & CO., INC., a corporation organized and existing under the laws of New Jersey ("Merck"), and METABASIS THERAPEUTICS, INC., a corporation organized and existing under the laws of Delaware ("Metabasis").
LICENSE AND RESEARCH COLLABORATION AGREEMENT BETWEEN RAYZEBIO, INC. AND PEPTIDREAM, INC. Dated August 4, 2020License and Research Collaboration Agreement • August 24th, 2023 • RayzeBio, Inc. • Pharmaceutical preparations • New York
This LICENSE AND RESEARCH COLLABORATION AGREEMENT (the “Agreement”), effective as of August 3, 2020 (the “Effective Date”), is entered into by and between RayzeBio, Inc., a Delaware corporation having a principal place of business at 9880 Campus Point Dr, Suite 410, San Diego, CA 92121 USA (“RayzeBio”), and PeptiDream, Inc., a Japanese corporation having a principal place of business at 3-25-23 Tonomachi, Kawasaki-Ku, Kawasaki-Shi, Kanagawa, JAPAN 210-0821 (“PeptiDream”). RayzeBio and PeptiDream each may be referred to herein individually as a “Party” or collectively as the “Parties.”
FIRST AMENDED AND RESTATED LICENSE AND RESEARCH COLLABORATION AGREEMENTLicense and Research Collaboration Agreement • March 9th, 2010 • Aveo Pharmaceuticals Inc • Pharmaceutical preparations • New Jersey
LICENSE AND RESEARCH COLLABORATION AGREEMENT BETWEEN SELECTA BIOSCIENCES, INC. AND SANOFI DATED AS OF NOVEMBER 27, 2012License and Research Collaboration Agreement • May 24th, 2016 • Selecta Biosciences Inc • Pharmaceutical preparations • New York
THIS LICENSE AND RESEARCH COLLABORATION AGREEMENT (this “Agreement”), dated as of November 27, 2012, is between SELECTA BIOSCIENCES, INC., a company duly organized and existing under the laws of the State of Delaware, with a principal place of business at 480 Arsenal Street, Building One, Watertown, MA 02472, for and on behalf of itself and its Affiliates (together with its Affiliates, collectively “Selecta”), and SANOFI, a société anonyme duly organized and validly existing under the laws of the Republic of France, having its principal executive offices located at 54 rue La Boétie, 75008 Paris, France, for and on behalf of itself and its Affiliates (together with its Affiliates, collectively “Sanofi”).
BETWEENLicense and Research Collaboration Agreement • November 4th, 2004 • Genelabs Technologies Inc /Ca • Pharmaceutical preparations • California
EXCLUSIVE LICENSE AND RESEARCH COLLABORATION AGREEMENT between IDENIX PHARMACEUTICALS, INC. and METABASIS THERAPEUTICS, INC.License and Research Collaboration Agreement • March 13th, 2007 • Metabasis Therapeutics Inc • Pharmaceutical preparations • New York
EXCLUSIVE LICENSE AND RESEARCH COLLABORATION AGREEMENT by and between COCRYSTAL PHARMA, INC. and MERCK SHARP & DOHME CORP.License and Research Collaboration Agreement • April 1st, 2019 • Cocrystal Pharma, Inc. • Pharmaceutical preparations • New York
This Agreement (this “Agreement”) is effective as of January 2, 2019 (the “Effective Date”), and is entered into by and between Cocrystal Pharma, Inc., a corporation organized and existing under the laws of Delaware (“Cocrystal”) and Merck Sharp & Dohme Corp., a corporation organized and existing under the laws of New Jersey (“Merck”).
LICENSE AND RESEARCH COLLABORATION AGREEMENT by and between MODEX THERAPEUTICS, INC., OPKO HEALTH, INC. (solely for purposes of sections 6.1 and 9.3) and MERCK SHARP & DOHME LLC Effective March 7, 2023License and Research Collaboration Agreement • May 3rd, 2023 • Opko Health, Inc. • Pharmaceutical preparations • New York
or other ownership interests representing the equity, the voting stock or general partnership interest are owned, controlled or held, directly or indirectly, by a corporation or business entity described in (a) or (b).
LICENSE and RESEARCH COLLABORATION AGREEMENT between MERCK & CO., INC. and SUNESIS PHARMACEUTICALS, INC. LICENSE AND RESEARCH COLLABORATION AGREEMENTLicense and Research Collaboration Agreement • January 27th, 2005 • Sunesis Pharmaceuticals Inc • Pharmaceutical preparations • New York
This LICENSE AND RESEARCH COLLABORATION AGREEMENT (the “Agreement”), effective as of July 22, 2004 (the “Effective Date”), is made by and between Sunesis Pharmaceuticals, Inc., a Delaware corporation, having a principal place of business at 341 Oyster Point Boulevard, South San Francisco, CA 94080 (“Sunesis”), and Merck & Co., Inc., a New Jersey corporation, having a principal place of business at One Merck Drive, Whitehouse Station, NJ 08889-0100 (“Merck”). Sunesis and Merck are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
LICENSE AND RESEARCH COLLABORATION AGREEMENT BETWEEN MERCK & CO., INC. AND DECODE GENETICS, EHF. LICENSE AND RESEARCH COLLABORATION AGREEMENTLicense and Research Collaboration Agreement • March 15th, 2007 • Decode Genetics Inc • Services-commercial physical & biological research • New Jersey
THIS RESEARCH COLLABORATION AND LICENSE AGREEMENT (this “Agreement”), which shall be effective as of February 25, 2004 (the “Effective Date”), is entered into by and between deCODE genetics, Ehf., a corporation organized under the laws of Iceland (“deCODE”) and Merck & Co., Inc., a corporation organized under the laws of the State of New Jersey, having an office located at One Merck Drive, Whitehouse Station, New Jersey 08889 (“MERCK”).
LICENSE AND RESEARCH COLLABORATION AGREEMENT between GENELABS TECHNOLOGIES, INC. and NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.License and Research Collaboration Agreement • August 3rd, 2006 • Genelabs Technologies Inc /Ca • Pharmaceutical preparations • New York
This Agreement (the “Agreement”) dated as of June 2, 2006 (the “Effective Date”) is made between Genelabs Technologies, Inc., a California corporation having its principal place of business at 505 Penobscot Drive, Redwood City, California 94063 (“Genelabs”), and Novartis Institutes for BioMedical Research, Inc., a Delaware corporation having its principal place of business at 250 Massachusetts Avenue, Cambridge, Massachusetts 02142 (“PHARMA”).
